Laleh Amiri-Kordestani, MD retweeted
Open access article in @TheCancerLetter worth reading. Discusses @FDAOncology Rick Pazdur's perspective on the oncology #drugshortage
This Post is from an account that no longer exists. Learn more
Laleh Amiri-Kordestani, MD retweeted
Applications are due August 15 for the 2022-23 FDA-AACR Oncology Educational Fellowship. Selected fellows will learn about oncology drug development and the regulatory review process while participating in mentoring and networking events. Learn more:
https://nitter.gq/t.co/NAezbSv5mE
Laleh Amiri-Kordestani, MD retweeted
A phenomenal place to work! @FDAOncology
This Post is from an account that no longer exists. Learn more
Laleh Amiri-Kordestani, MD retweeted
Randomized clinical trial designs are sometimes not feasible. This review article in Annals of Oncology discusses the concept of external control arms as a way to circumvent this caveat.
annalsofoncology.org/article…
@pmishrakalyani @DrJuliaBeaver @realrickpazdur
Laleh Amiri-Kordestani, MD retweeted
#FDAapproves treatment for adult women and men with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer: go.usa.gov/xesMJ and go.usa.gov/xesMS
Laleh Amiri-Kordestani, MD retweeted
From @MedMtgNews: #SABCS21 Recap: A session yesterday offered insight into recent @FDAOncology approvals. ow.ly/MC3v50H7560 @montero_md #bcsm
Laleh Amiri-Kordestani, MD retweeted
Preliminary OS results of MonarchE in overall pop and in the pop where the drug is approved by FDA . MonarchE assessed efficacy of Abemaciclib , a CDK4/6 inh in pts with HR+/her2- eBChttps://www.annalsofoncology.org/article/S0923-7534(21)04551-8/fulltext#.YXxIy37LgUA.twitter
Laleh Amiri-Kordestani, MD retweeted
FDA issued a final guidance describing the considerations for using metastasis-free survival (MFS) as an endpoint in clinical trials for cancer drugs or biological products in patients with nonmetastatic castration-resistant prostate cancer: go.usa.gov/xFnuM
Laleh Amiri-Kordestani, MD retweeted
Outcomes in older men with non-metastatic CRPC treated with androgen receptor inhibitors: an @FDAOncology pooled analysis, now available online @TheLancetOncol #pcsm authors.elsevier.com/a/1dScp…
Laleh Amiri-Kordestani, MD retweeted
Thank you to all my nursing colleagues for everything you do for your patients and their families! In addition to front line care, plenty of phenomenal nurses contributing to research and policy... @FDAOncology is just one good example.
To nurses across the United States going above and beyond to keep us safe, thank you. RT this message to show the nurses in your feed how much you appreciate them 💙 #NationalNursesDay #NW2021
Laleh Amiri-Kordestani, MD retweeted
SPECIAL REPORT: Ever heard of “dangling” accelerated approvals? We ask @FDAOncology's @realrickpazdur and Julia Beaver to explain the term—and this week’s ODAC agenda. cancerletter.com/conversatio…
Laleh Amiri-Kordestani, MD retweeted
*Just Released* @FDAOncology annual report for 2020... A broad range of review, science, engagement and policy efforts completed by #OCE and #FDA scientists across the agency to benefit cancer patients in a very challenging year... fda.gov/about-fda/oncology-c…
Laleh Amiri-Kordestani, MD retweeted
Deadline is Jan 28 for submission of white papers to apply for funding opportunities in several important priority research areas to advance oncology drug development...
This Post is from an account that no longer exists. Learn more
Laleh Amiri-Kordestani, MD retweeted
Great annual advocate chat with the FDA yesterday at #SABCS2020. If you are a cancer patient/advocate and looking to engage with the FDA, you can follow @FDAOncology in Twitter, and you can also visit fda.gov/patients for more information – at Washington, DC
Congratulations @jrgralow
2
Laleh Amiri-Kordestani, MD retweeted
#ProjectOrbis is an @FDAoncology initiative which supports concurrent submission/review by multiple international regulatory authorities- in this case- Health Canada, Australian Therapeutic Goods Administration, Switzerland’s Swissmedic, and Singapore Health Sciences Authority
Laleh Amiri-Kordestani, MD retweeted
Many regulatory insights in this summary #bcsm:
- @FDAOncology encourages inclusion of patients with #breastcancer #brainmetastases and indication specifically notes this important and unmet need population
- indication includes #malebreastcancer
- Project Orbis application
This Post is from an account that no longer exists. Learn more




















